Pain Management News and Research

RSS

DJOFL third quarter net sales decrease to $233.6 million

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC ("DJOFL"), for the third quarter of 2010, ended October 2, 2010.

4 Nov 2010

New noninvasive technique provides low-level electrical stimulation to reduce pain

A simple, noninvasive technique providing low-level electrical stimulation of the brain produces significant pain-reducing effects in humans, reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

3 Nov 2010

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

3 Nov 2010

American Anesthesiology acquires Greensboro Anesthesia Physicians

American Anesthesiology, a subsidiary of MEDNAX, Inc., today announced the acquisition of Greensboro Anesthesia Physicians, P.C., a physician group practice that provides patient services at three hospitals within the Moses Cone Health System and two surgery centers in the Greensboro, NC, metropolitan area.

1 Nov 2010

Physicians suggest tips to overcome acute pain

The truth is not all pain is created equal. Acute pain is where it all begins. Lasting for several months, acute pain is typically treated with rest, time and medication. For many, that is enough. But if the pain persists, it converts to chronic pain, and new methods must be explored.

29 Oct 2010

Researchers to develop tailor-made pain management strategies for chronic pain

Research presented at this year's American Society of Anesthesiologists Annual Meeting offers new data in the quest to develop tailor-made pain management strategies based upon a patient's genetic predisposition and other important factors.

20 Oct 2010

Few legitimate opioid users are getting information to keep medications safe

For some people with ongoing or chronic pain, opioids (medications such as oxycodone or hydrocodone) can make the difference between disability and the ability to function at near-normal levels. For those with acute pain, such as pain after surgery or injury, sound pain management with opioids can speed healing and recovery.

19 Oct 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

IASP sponsors campaign for acute pain management

The Global Year Against Acute Pain launches today, focusing attention on a widely under-assessed and undertreated pain that affects most people throughout their lives. Sponsored by the International Association for the Study of Pain (IASP), the 12-month campaign focuses on education for health care professional and government leaders as well as public awareness to help lessen the gap between existing knowledge and technology for acute pain control and current pain management practice.

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

ASA to salute U.S. military members at 2010 Annual Meeting

The American Society of Anesthesiologists (ASA) will salute its military members as well as all U.S. service members and their families during the Society's 2010 Annual Meeting in San Diego, CA, October 16 - 20.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Integrated Research Network to analyze payor health policy for chronic pain medications

HealthCore's Integrated Research Network is enrolling family physicians, general practitioners, internists, neurologists, rheumatologists, endocrinologists, and pain management specialists in a first-of-its-kind study to analyze payor health policy for chronic pain medications.

12 Oct 2010

EONS launches new initiative to improve pain management for cancer patients

The European Oncology Nursing Society launches first European nurse initiative to examine current practices in breakthrough cancer pain and look at ways of improving patient outcomes in palliative care

7 Oct 2010

AOA launches 'Break Through Your Pain' public education campaign

If you're living in pain, you're certainly not alone. According to a new survey released today by the American Osteopathic Association (AOA) nearly 70% of Americans report that they, or someone they care for, have experienced pain during the past 30 days. While Congress declared 2000 to 2010 the "Decade of Pain Control and Research," chronic, or reoccurring pain still affects more Americans than cancer, diabetes and heart disease combined. In fact, more than 76 million people live in pain every day.

6 Oct 2010

Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects

A new drug called repinotan blocks the respiratory depressant effects of morphine-like opioid drugs—without altering their potent pain-relieving effects, according to a study in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

6 Oct 2010

American Anesthesiology acquires Southeast Anesthesiology Consultants

American Anesthesiology, a subsidiary of MEDNAX, Inc., today announced the acquisition of Southeast Anesthesiology Consultants, P.A., a physician group practice that provides anesthesia care and pain management services at nine hospitals, 12 ambulatory surgery centers and 10 pain management centers principally located in the Charlotte, NC, metropolitan area.

5 Oct 2010

Some Minn. insurers will end certain Medicare plans; Utah issues rule on child-only plans; Fla. law on pain clinics takes effect

Five insurance companies including Minnetonka-based Medica next year will stop providing a particular type of Medicare health plan in much of Minnesota, a state official said Thursday.

4 Oct 2010

AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system

AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.

1 Oct 2010